Calistoga Pharmaceuticals Appoints Andrew Guggenhime as Chief Financial Officer

SEATTLE--(BUSINESS WIRE)--Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the appointment of Andrew L. Guggenhime as Chief Financial Officer.

Back to news